Nebivolol Accord

Nebivolol, the active ingredient in Nebivolol Accord, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and heart failure in adult patients, where reduction of blood pressure and improvement of cardiac function are required. Nebivolol works by selectively blocking β1‑adrenergic receptors and enhancing nitric‑oxide mediated vasodilation, which together lower peripheral resistance.

GNH USA supplies Nebivolol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is used within the cardiovascular therapeutic area to control blood pressure and support heart function. - Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction. - Heart failure: improves left ventricular ejection fraction and decreases symptoms such as dyspnea and fatigue. - Post‑myocardial infarction (when indicated): helps prevent adverse cardiac remodeling and recurrent ischemic events.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness or light‑headedness: related to blood pressure lowering. - Fatigue or tiredness: may be noticeable during dose titration. - Bradycardia: slower than normal heart rate. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping to dangerously low levels. - Symptomatic hypotension: marked drop in blood pressure causing fainting. - Heart block: impairment of electrical conduction. - Bronchospasm: especially in patients with reactive airway disease. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

Before initiating Nebivolol therapy, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Cardiac function evaluation: review baseline heart rate and ECG for conduction abnormalities. - Concomitant beta‑blocker use: avoid duplicate therapy that may increase bradycardia risk. - Hepatic impairment: dose adjustment may be needed in patients with liver dysfunction. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects may cause severe bradycardia. - Calcium‑channel blockers (verapamil, diltiazem): can enhance bradycardia and AV‑block. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: risk of orthostatic hypotension when combined. - Antidiabetic agents: nebivolol may mask hypoglycemia symptoms; monitor glucose levels.